Euroespes

What Euroespes does

Euroespes S.A. operates the Centro Internacional de Neurociencias y Medicina Genómica, a specialized medical center headquartered in Bergondo, A Coruña, Spain, founded in 1991 by Dr. Ramón Cacabelos. The company delivers prevention, diagnosis, and treatment services focused on Central Nervous System disorders — principally Alzheimer's disease, Parkinson's disease, and cerebrovascular conditions — through an integrated 10-step diagnostic protocol that combines clinical examination, in-house laboratory analysis, imaging, neuropsychological evaluation, genomic sequencing, pharmacogenetic profiling, and epigenetic biomarker testing. It serves a mix of Spanish and international patients across seven defined use-case segments, including neurodegenerative disease patients, corporate executives, children with neurodevelopmental disorders, and health-conscious individuals seeking predictive genetic risk assessment.

The underlying technology base is genomic medicine rather than software: proprietary Next Generation Sequencing (NGS) exome analysis, a Smart Pharmacogenetic Card (PGx-60/4000) delivered via USB or web, global DNA methylation and miRNA-based epigenetic biomarkers, and the AtreMorine (E-PodoFavalin-15999) nutraceutical compound derived from Vicia faba L. with reported 200-300x dopamine increase for Parkinson's patients. Euroespes holds 24 patents and operates wholly-owned subsidiaries EuroEspes Biotecnología, S.A. (biotech manufacturing) and the digital platform MyLogy Genomics. The firm markets itself as the only provider of the Smart Pharmacogenetic Card system in Spain.

The business model is fee-for-service diagnostics combined with product sales: revenue is generated from comprehensive diagnostic protocols (quote-based, single-day), genetic risk panels and home testing kits, the AtreMorine nutraceutical, and recurring access to pharmacogenetic profiles. Go-to-market is sales-led and direct-to-consumer, supported by an international patients division, multilingual website, corporate executive health programs, and earned media through press and scientific publications. Pricing is not publicly disclosed. The company is publicly listed on the BME under ticker EEP and reports 51–100 employees. Note: a five-year financial table provided in source data contains figures inconsistent with the company's size (revenue in trillions of dollars) and is treated as erroneous; the firm's own materials state revenue is not publicly disclosed.

Name

Euroespes

Legal name

Euroespes S.A.

Website

https://euroespes.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

51–100 employees

Short description

Euroespes operates an international medical center in A Coruña, Spain, specializing in neurological diseases (Alzheimer's, Parkinson's) using genomic medicine, pharmacogenetic profiling, and proprietary nutraceuticals. It serves Spanish and international patients with personalized diagnostics and treatment.

Ownership category

akta.pro rank

Product category

Genomic Medicine & Neurosciences

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

akta.pro secondary industries

Pharmacogenomics (PGx) Decision Support (HLAAANAB), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Genomic medicine services
• Pharmacogenetic testing
• Neurological diagnostics
• Predictive genetic testing
• Personalized treatment protocols

Headquarters

HQ city

Corunna

HQ country

Spain

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Medical Consultation and Diagnostic Services: Revenue generated from comprehensive medical consultations, diagnostic protocols, and specialized tests for neurological and genomic conditions. Services include pharmacogenetic profiling, epigenetic testing, and preventive health assessments.
2. AtreMorine Nutraceutical Sales: Sale of AtreMorine, a proprietary nutraceutical product for Parkinson's disease treatment, manufactured at Ebiotec biotechnology plant.
3. Genetic Testing Panels: Sale of genetic risk panels for various conditions including Alzheimer's, Parkinson's, cardiovascular diseases, metabolic disorders, and food intolerances.
4. Smart Pharmacogenetic Card: Bioinformatics tools provided to patients containing their pharmacogenetic profiles for ongoing personalized treatment guidance.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Euroespes operates an international medical center that delivers prevention, diagnosis, and treatment services for Central Nervous System diseases through personalized genomic medicine. Its core offering is a comprehensive 10-step Diagnostic Protocol combining clinical examination, laboratory testing, digital diagnostics (brain mapping, EEG, optical topography), neuropsychological evaluation, genomic diagnosis via NGS, pharmacogenetic profiling, and epigenetic biomarkers, completed in a single day. It also sells proprietary nutraceuticals (AtreMorine for Parkinson's), genetic risk panels for predictive testing, and the Smart Pharmacogenetic Card for ongoing personalized drug guidance.

Product overview

EuroEspes is an international medical center specializing in neuroscience and genomic medicine, offering a comprehensive integrated platform for disease prevention, diagnosis, and treatment. The core offering centers on the Centro Médico EuroEspes, which provides specialized prevention plans for Alzheimer's, Parkinson's, and cerebrovascular diseases, supported by a 10-step Diagnostic Protocol encompassing medical examination, laboratory analysis, imaging, digital diagnostics, neuropsychological evaluation, genomic diagnosis, and pharmacogenetic profiling. Key products and services include Digital Diagnostics (brain mapping and optical topography), an in-house Clinical Laboratory with same-day results, the FoodSens IgG food sensitivity test (287 foods), and the AtreMorine nutraceutical for Parkinson's patients. The product portfolio extends through Predictive Genetics panels, Diagnostic Genetics, Epigenetic Biomarker testing, and Pharmacogenetics services, with the MyloGy Genomics digital platform providing patients and physicians with pharmacogenetic profile access. All services are coordinated through the International Center for Neurosciences and Genomic Medicine under Dr. Ramón Cacabelos's leadership.

Differentiator

Problem solved

Functional benefit

Brands

• AtreMorine: A neuroprotective nutraceutical product developed by EuroEspes researchers for Parkinson's disease patients, manufactured at the Ebiotec biotechnology plant
• MyLogy Genomics
• EuroPharmaGenics
• Pharmacogenomics Guide
• Gen-T Magazine

Products and services

• Centro Médico EuroEspes (EuroEspes Medical Center) International reference medical center with 30 years of experience in prevention, diagnosis, and treatment of Central Nervous System diseases (Alzheimer's, Parkinson's) through Personalized Medicine and Genomics, serving patients in Bergondo, A Coruña with international patient services.
• Comprehensive Diagnostic Protocol 10-step diagnostic protocol including medical examination, laboratory analysis, imaging tests, digital diagnostics, neuropsychological evaluation, genomic diagnosis, pharmacogenetic profiling, epigenetic biomarkers, comprehensive medical report, and Smart Pharmacogenetic Card, all completed in a single day.
• Alzheimer Prevention Plan Clinical protocol for Alzheimer's disease diagnosis, treatment, and prevention using genomic medicine and treatment personalization, including genetic panels, pharmacogenetic profiles, and epigenetic biomarkers.
• Parkinson Prevention Plan Clinical protocol for Parkinson's disease diagnosis, treatment, and prevention incorporating genetic panels, pharmacogenetic profiling, and the proprietary AtreMorine nutraceutical.
• AtreMorine (E-PodoFavalin-15999) Proprietary neuroprotective nutraceutical bioproduct derived from Vicia faba L. (a natural L-dopa source) designed for Parkinson's patients, demonstrating a 200-300x dopamine increase over basal levels with neuroprotective effects on dopaminergic neurons, manufactured at the Ebiotec biotechnology plant.
• Cerebrovascular Disease Prevention Plan Prevention, diagnosis, and treatment protocol for cerebrovascular diseases including stroke, addressing stroke risk, vascular cognitive impairment, and cardiovascular comorbidities.
• Children Prevention Plan (Neurodevelopmental Assessment) Early diagnosis pathway for children with learning difficulties, ADHD, autism spectrum disorders, and genetic diseases, addressing school failure, attention deficits, behavioral disorders, and brain maturation issues.
• Executive Prevention Plan Comprehensive genomic preventive health assessments for corporate executives and senior managers, addressing cardiovascular risk, cerebrovascular risk, stress-related disorders, and work-life balance with pharmacogenetic-guided treatments.
• Predictive Genetics Panels Genetic risk assessment panels for complex diseases including Alzheimer's, Parkinson's, cardiovascular, cerebrovascular, metabolic conditions, and food intolerances, available via home testing kit or at the medical center.
• Diagnostic Genetics Monogenic genetic disease diagnosis and testing following Mendelian inheritance patterns for over 6,000 known monogenic diseases.
• Epigenetic Biomarker Testing Epigenetic testing including global DNA methylation analysis, pyrosequencing for gene-specific methylation (including Septin 9 for colorectal cancer), gene expression studies via RT-qPCR, and miRNA profiling for early disease detection and treatment monitoring.
• Smart Pharmacogenetic Card (Pharmacogenetics Service) Personalized drug treatment guidance based on individual pharmacogenetic profiles (PGx-60/4000), issued as the Smart Pharmacogenetic Card in either physical USB form or virtual digital access via the MyloGy Genomics platform.
• FoodSens (IgG Food Sensitivity Test) Food sensitivity multiplex test based on ELISA method measuring IgG antibodies against 287 food antigens using IgG Food Explorer technology, providing personalized dietary intervention guidance.
• Clinical Laboratory Services In-house clinical analysis laboratory providing immediate same-day results with specialized testing in biochemistry, hematology, immunology, hormones, tumor markers, neurotransmitters, drug monitoring, and microbiology.
• Digital Diagnostics (Brain Mapping and Optical Topography) Real-time brain function study using non-invasive techniques including brain mapping, electroencephalogram (EEG), sleep studies, and optical topography for neurological and psychiatric disease diagnosis.
• Radiodiagnostics (Imaging) Advanced imaging services including open MRI (for claustrophobic patients), computed axial tomography (CT scan), conventional radiology, conventional and transcranial ultrasound, and bone densitometry.
• Neuropsychology Services Neuropsychological assessment services for cognitive and psychological state evaluation, including protocols for neurodegenerative diseases, acquired brain injury, psychiatric pathologies, and neurodevelopmental disorders.
• MyloGy Genomics Platform Digital platform that enables drug treatment personalization based on each person's genetic profile, providing patients and physicians with access to pharmacogenetic profile information.

Quantifiable outcome

• Only 20-30% of available treatments are effective in neurological disorders. 60% are inefficient, 20% have no effect, 30-40% cause toxicity.
• +2 more outcomes

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

Three partnerships are on record, tiered minor.

• Universidad Sechenov, MoscowminorStrategic or Co-development Partner · 1 January 2020Dr. Ramón Cacabelos serves as a Professor at the Faculty of Medicine of the Universidad Sechenov in Moscow, Russia, indicating an academic collaboration.
• Universidad Continental, PeruminorStrategic or Co-development Partner · 1 January 2017Dr. Cacabelos holds a Chair of Genomic Medicine at Universidad Continental in Huancayo, Peru, indicating academic and research collaboration.
• Universidad Camilo José Cela, MadridminorStrategic or Co-development Partner · 1 January 2013Dr. Cacabelos served as Cátedra de Medicina Genómica and Vice-Rector of Research and Science. Founded EuroEspes Biotechnology Chair at this university.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Synlab: Synlab operates one of Europe's largest medical diagnostic laboratory networks, providing clinical chemistry, genetics, and specialty testing. It is comparable to Euroespes' in-house clinical laboratory capabilities but serves a much broader menu and geography.
• Eurofins Genomics: Eurofins Genomics is a global provider of genomic services including sequencing, genotyping, and pharmacogenomics. It overlaps with Euroespes' laboratory and pharmacogenetic capabilities at much larger scale but does not deliver integrated neurological clinical care.
• Unilabs: Unilabs is a major European clinical diagnostics and specialty testing provider, including genetic and pharmacogenomic testing. It is comparable to Euroespes' laboratory and specialty diagnostics services, though with far broader geographic and test coverage.

Emerging players

• Quanterix: Quanterix develops ultra-sensitive immunoassay platforms (Simoa) for neurological biomarkers, including for Alzheimer's and Parkinson's disease. It supplies the kind of high-sensitivity biomarker detection technology underlying Euroespes' neurodegenerative diagnostic protocols.
• Helix: Helix operates a DNA sequencing platform powering population genomics, clinical genomics, and pharmacogenomic applications. It overlaps with Euroespes' NGS-based genomic and PGx offerings, with a platform business model rather than a clinical-services model.
• Centogene: Centogene provides rare disease genetic diagnostics, pharmacogenomics, and clinical-genomics services globally. It overlaps with Euroespes in genetic diagnostics and pharmacogenomics, particularly for monogenic diseases and complex disorders.
• Dante Labs: Dante Labs offers whole-genome sequencing, pharmacogenomics, and personalized health reports direct to consumers. It competes with Euroespes' predictive genetics and NGS-based diagnostic offerings, though with a D2C model rather than an integrated clinical protocol.

Direct peers

• C2N Diagnostics: C2N Diagnostics offers blood-based biomarker tests (PrecivityAD) for early Alzheimer's detection and is developing CNS diagnostic products. Like Euroespes, it focuses on neurological disease diagnostics with a precision-medicine angle, though it is a diagnostics-product company rather than an integrated clinic.
• Mapmygenome: Mapmygenome is an India-based molecular diagnostics and personalized genomics company offering predictive genetic tests, pharmacogenomics panels, and clinical genomics services. It mirrors Euroespes' combination of predictive genetics, PGx, and lifestyle-focused genetic counseling.
• Amprion: Amprion develops seed amplification assays (SAAlyt) for misfolded protein detection in neurodegenerative diseases including Parkinson's and Alzheimer's. It is a direct peer in CNS biomarker diagnostics, competing in the same neurological disease detection category Euroespes serves.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/EuroEspes
• LinkedInlinkedin.com/company/euroespes

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Euroespes